Results 71 to 80 of about 9,731 (210)

Elexacaftor–Tezacaftor–Ivacaftor Reduces Revision Sinus Surgery in People With Cystic Fibrosis

The Laryngoscope, Volume 136, Issue 5, Page 2048-2053, May 2026.
Elexacaftor–tezacaftor–ivacaftor (ETI) was associated with a significant decrease in the frequency and rate of endoscopic sinus surgeries in patients with cystic fibrosis. These findings suggest an improvement in CF‐related chronic rhinosinusitis outcomes following ETI and may influence future CF treatment decisions.
Amy Lin, Makanko Komara, Isaac Kistler, Zheng Hong Tan, Meredith Lind, Kavitha Kotha, Tendy Chiang   +6 more
wiley   +1 more source

Successes and Challenges: Inhaled Treatment Approaches Using Magnetic Nanoparticles in Cystic Fibrosis

Magnetochemistry, 2020
Magnetic nanoparticles have been largely applied to increase the efficacy of antibiotics due to passive accumulation provided by enhancing permeability and retention, which is essential for the treatment of lung infections. Recurring lung infections such
Marsha Tan, Felisa Reyes-Ortega, Elena K. Schneider-Futschik   +2 more
doaj   +1 more source

Restoring Cystic Fibrosis Transmembrane Conductance Regulator Function Reduces Airway Bacteria and Inflammation in People with Cystic Fibrosis and Chronic Lung Infections [PDF]

, 2017
Rationale: Previous work indicates that ivacaftor improves cystic fibrosis transmembrane conductance regulator (CFTR) activity and lung function in people with cystic fibrosis and G551D-CFTR mutations but does not reduce density of bacteria or markers of
Accurso, Frank J., Adam, Ryan J., Bruce, James E., Carter, Suzanne, Cooke, Gordon, Donnelly, Seamas C., Edwards, Rachael M., Gallagher, Charles, Grogan, Brenda, Heltshe, Sonya L., Hisert, Katherine B., Hoffman, Lucas R., Jorth, Peter, Launspach, Jan L., McKone, Edward F., Pope, Christopher, Radey, Matthew, Singh, Pradeep K., Stoltz, David, Welsh, Michael J., Wolter, Daniel J., Wu, Xia   +21 more
core   +2 more sources

Challenges to Assessing the Prevalence of Cystic Fibrosis in the Caribbean

Pediatric Pulmonology, Volume 61, Issue 5, May 2026.
ABSTRACT Cystic fibrosis (CF) is likely underdiagnosed in Caribbean populations due to non‐representative cystic fibrosis transmembrane conductance regulator (CFTR) variant screening panels, limited newborn screening programs, and structural healthcare barriers.
Krystal L. Rivera‐Figueroa, Cole L. Martin, Christina A. Le, Wilfredo De Jesús Rojas, Leandra Cordero Oñate, Stephen G. Aller   +5 more
wiley   +1 more source

Chronic inflammation in CF airways - a persistent issue for A20 [PDF]

, 2016
Cystic Fibrosis (CF) is characterised by prolonged and exaggerated airways inflammation. Despite recent developments to overcome the underlying functional defect in CFTR (cystic fibrosis transmembrane conductance regulator), there is still an unmet need ...
El Banna, Amal, Ennis, Madeleine, McCollum, Kirsten, Schock, Bettina   +3 more
core   +1 more source

Pharmacogenomic testing and its future in community pharmacy [PDF]

, 2020
Although it is common to see pharmacogenomic testing used North America and Australia, it is not yet part of practice in the UK. With the promise of genomic screening becoming part of the NHS, pharmacists must equip themselves with a knowledge of how the
Wright, David, Youssef, Essra
core   +1 more source

Utility of Fecal Elastase‐1 in Estimating Exocrine Pancreatic Function in Cystic Fibrosis: A Scoping Review

Pediatric Pulmonology, Volume 61, Issue 5, May 2026.
ABSTRACT Background In people with cystic fibrosis (pwCF), identification of exocrine pancreatic insufficiency (EPI) is essential to prevent steatorrhea and, if not managed actively, can lead to catastrophic consequences. Fecal elastase‐1 (FE‐1) is a widely used test to screen for EPI in cystic fibrosis (CF).
Senthilkumar Sankararaman, Sara Hendrix, Mandy Neudecker, Drucy Borowitz   +3 more
wiley   +1 more source

A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis [PDF]

, 2017
Background: Studies are required that evaluate real-world outcomes of inhaled aztreonam lysine in patients with cystic fibrosis (CF). Methods: Our treatment-evaluator tool assessed the effectiveness of inhaled aztreonam in routine practice in 117 CF ...
Amadori, Andrew M Jones, Assael, Barry, Barry J Plant, Bell, Britto, Cano Megías, Cedric Gunaratnam, Charles S Haworth, Cherniak, Damian G Downey, Daniel G Peckham, Davies, de Boer, Diana Bilton, Döring, Edward F McKone, Flume, Garrison, Harrison, Herland, Joe A Eustace, Kerem, Liou, McCoy, McKone, Mogayzel, National Research Ethics Service (NRES), Oermann, Plant, Quittner, R. Ian Ketchell, Retsch-Bogart, Roche, Sanders, Steinkamp   +36 more
core   +1 more source

Function and Structure Relationships With Inflammation Differ in Two Chronic Suppurative Lung Diseases

Pediatric Pulmonology, Volume 61, Issue 5, May 2026.
ABSTRACT Rationale Cystic fibrosis (CF) and primary ciliary dyskinesia (PCD) are characterized by neutrophilic airway inflammation but differ in clinical features. Objectives We investigated relationships of pulmonary and systemic inflammatory markers with functional and structural lung disease.
Teresa Fuchs, Jacqueline Donovan, Andrew Ives, Samantha Irving, Gwyneth Davies, Claire Hogg, Eric Alton, Gemma Wilson, Andrew Bush, Jane C. Davies   +9 more
wiley   +1 more source

Colorectal Cancer Complicated by Pulmonary Embolism and Potential Takotsubo Cardiomyopathy in a Person With Cystic Fibrosis: Diagnostic and Management Considerations

Respirology Case Reports, Volume 14, Issue 5, May 2026.
We describe a complex case of pulmonary embolism and dilated cardiomyopathy in a person with cystic fibrosis. These late complications occurred following laparoscopic left hemicolectomy for colonic adenocarcinoma. This case highlights the complexities of evaluating breathlessness in severe lung disease, and the management challenges that arise as life ...
Laura Frederiksen, James Brown, Vanessa Moore, David W. Reid   +3 more
wiley   +1 more source